In a statement, the health technology assessment (HTA) organisation said that the two drugs were backed after an agreement with the two developers on pricing that will make them an option for around 3,450 NHS patients.
Trodelvy (sacituzumab govitecan) can be used for unresectable triple-negative breast cancer (TNBC) that can’t be treated with surgery, after two or more prior rounds of therapy.
The antibody-drug conjugate (ADC) was turned down by NICE in draft guidance published earlier this year, leading to concerns of a disparity in access to the drug as the Scottish Medicines Consortium (SMC) had already cleared its use.
